Plasminogen activators (PAs) play an important role in tumor cell invasion. We have analysed the expression of tissue-type PA (t-PA), urokinase-type PA (u-PA), and their respective receptors, annexin II and u-PAR, in normal and neoplastic cultures of pancreatic cells, as well as in pancreatic tissues, and have examined their role in tumor invasiveness in vitro. Using Northern blotting, Western blotting, and ELISA, t-PA is detected in cultured pancreas cancer cells displaying a well dierentiated phenotype but it is undetectable in less dierentiated cells and in normal pancreatic cultures. In contrast, u-PA transcripts, protein, and enzymatic activity are detected both in cancer cells and in normal cultures. Higher levels of u-PAR and annexin II are present in cancer cells than in normal cultures and, in SK-PC-1 cells, both receptors are localized in the basolateral membrane. In vitro invasion assays indicate that both t-PA and u-PA contribute to the invasiveness of SK-PC-1 cells through reconstituted extracellular matrix. To determine the relevance of these studies to pancreas cancer, immunohistochemical assays have been used to examine the expression of t-PA, u-PA, and their receptors in normal and neoplastic tissues. t-PA is absent from normal pancreas and from tumor associated pancreatitis, whereas it is detected in the majority of pancreas cancer tissues (16/17). Annexin II is also overexpressed in some tumors (5/13). u-PAR is overexpressed in most tumor samples examined (14/15), while u-PA is weakly detected in a low number of cases (3/14); both u-PAR and u-PA are overexpressed in areas of tumor associated pancreatitis. Indirect evidences indicate that K-ras and p53 mutated proteins can regulate the expression of PAs. In pancreatic cancer
Introduction
Cancer of the exocrine pancreas is a highly aggressive tumor: it represents the fourth cause of cancer death in the United States and its 5-year survival rate is less than 2% (reviewed in Warshaw, 1992) . The causes of its clinical behavior are not known. The tumor's biological features, genetic or epigenetic, may be at the basis of its aggressiveness. Alternatively, certain characteristics of the pancreas, such as the paucity of the connective tissue or the lack of a capsule, may also participate. The majority of exocrine pancreatic tumors are classi®ed as`ductal adenocarcinomas' on the basis of their microscopic appearance. The study of the molecular biology of these tumors has revealed that quantitative and qualitative changes in gene expression occur during their evolution. Point mutations in K-ras (Smit et al., 1988; Hoorens et al., 1993; Berrozpe et al., 1994; Caldas et al., 1994b) , deletions and mutations in p53 (Hollstein et al., 1991; Hoorens et al., 1993) , MTS-1 (Caldas et al., 1994a) and DPC-4 (Hahn et al., 1996) , and overexpression of several genes potentially involved in tumor establishment and progression have been described (reviewed in Friess et al., 1996) . Epigenetic changes, i.e. the overexpression of growth factor receptors and their ligands such as c-met/HGF, can lead to the activation of autocrine and paracrine loops enhancing protease secretion, tumor cell motility, and invasiveness in vitro and in experimental models (Bellusci et al., 1994; Jeers et al., 1996; Burfeind et al., 1996; Paciucci et al., submitted) . The biological relevance of these alterations is suggested by their association with a worse prognosis (reviewed in Friess et al., 1996) .
To get further insight into the molecular basis of pancreas cancer, we set to identify cDNAs overexpressed in SK-PC-1 pancreas cancer cells but not in normal pancreas tissue using a subtractive hybridization technique. Preliminary results using this strategy suggested that overexpression of tissue-type plasminogen activator (t-PA) might be relevant to this tumor (Paciucci et al., 1996) . The plasminogen proteolytic system plays a central role in tumor cell invasion mediated by secreted proteases (Mignatti et al., 1986) . In addition to its recognized role in degrading extracellular matrix proteins, plasmin can activate several latent metalloproteases relevant for malignant cell invasion (He et al., 1989; Knauper et al., 1996) and plasmin or PAs can activate latent growth factors like HGF and TGFb which may contribute to tumor development and spreading (Sato and Rifkin, 1989; Lyons et al., 1990; Mars et al., 1993; Naldini et al., 1992) . t-PA, and especially urokinase (u-PA), have been shown to be overexpressed in a variety of human tumors (reviewed in Dano et al., 1985, and in Kwaan, 1992) . The complex formed by u-PA bound to its membrane receptor (u-PAR) is an important component of the cell migration machinery, providing an inducible, localized cell surface proteolytic activity that is related to the invasive properties of cells (reviewed in Blasi, 1996) . Thus, increased expression of u-PA and u-PAR in tumor cells has been correlated with increased invasive potential in vitro and metastatic activity in vivo (Ossowski, 1988; Ossowski et al., 1991; Pyke et al., 1995; Wei et al., 1996) . Furthermore, an increased production of u-PA and u-PAR is associated with a poor prognosis in breast cancer (Nielsen et al., 1996) and other tumors (Hsu et al., 1995; Verspaget et al., 1995) . By contrast, there is less evidence for a role of t-PA in tumor progression, though its overexpression has also been reported in selected tumor types (Wilson et al., 1983; Wilson and Francis, 1987; De Vries et al., 1994; Moser et al., 1994) . The mechanism of action of t-PA in invasive processes is not completely clear. Its interaction with an endothelial cell membrane receptor speci®c for t-PA/plasminogen, identi®ed as annexin II, is likely to be involved in endothelial cell migration (Hajjar et al., , 1996 . In tumor invasion, no data are available to con®rm a similar mechanism and no reports have analysed the expression of annexin II in relationship with t-PA production.
To obtain further information about the contribution of t-PA to the aggressiveness of pancreatic tumors, we have taken advantage of the availability of a panel of well characterized pancreas cancer cell lines (VilaÂ et al., 1994a (VilaÂ et al., , 1995a and of normal exocrine pancreas cultures (VilaÂ et al., 1994b) . We have investigated the expression of t-PA, u-PA and their receptors in these cells and have assessed the relative contribution of the two PAs to the invasive phenotype in vitro. In addition, we have analysed the expression of the PA system components in normal and neoplastic pancreas tissues. Our ®ndings support that t-PA overexpression is selectively associated with neoplastic transformation of pancreatic epithelial cells and may contribute to their invasive potential.
Results

Expression of proteases in cultured human pancreatic cells
To investigate the expression of t-PA and u-PA genes in pancreatic epithelial cells in vitro we used normal primary pancreatic cultures displaying a ductal phenotype (NPC) and a panel of tumor cell lines selected on the basis of their dierentiation properties: SK-PC-1, MZ-PC-2, IMIM-PC-2 and Capan-1 display a dierentiated phenotype resembling that of normal duct cells, RWP-1 is moderately dierentiated, and IMIM-PC-1, SK-PC-3, Hs766T, Panc-1, BxPC-3 and AsPC-1 show a less dierentiated phenotype (VilaÂ et al., 1994a, and unpublished results) . SW979 and SW850 cells are derived from exocrine pancreas tumors, while QGP-1 cells are derived from an endocrine tumor. The phenotypic characteristics of these three lines have not been analysed in detail. Figure 1a shows that the levels of t-PA transcripts are high in 5/5 dierentiated or moderately dierentiated cell lines but are undetectable in 5/6 undierentiated cells and in NPC. In contrast, u-PA transcripts are detected both in pancreas cancer cell lines, regardless of the dierentiation phenotype, and in NPC.
Protease secretion in the conditioned medium of cultured cells was evaluated using ELISA assays ( Figure 1b and gel zymography (Figure 1c and d) . The level of secreted immunoreactive t-PA correlates well with the mRNA levels by Northern blotting. No secretion of t-PA is detected in the conditioned medium from Hs766T, Panc-1, BxPC-3, or QGP-1 cancer cells nor in NPC (Figure 1b and data not shown). Figure 1c shows that secreted u-PA enzyme, corresponding to the 54 kDa lytic band in the plasminogen-gelatin zymogram, is detected in all cell lines examined, including NPC, whereas secreted t-PA is detected in SK-PC-1, IMIM-PC-2, and SK-PC-3 tumor cells, but not in NPC. The proteolytic activity of proteins with mobilities of 92 kDa and 72 kDa likely correspond to the two forms of MMP9/ Gelatinase B and/or MMP2/Gelatinase A metalloproteases, respectively, since they are also detected in the gelatin zymogram ( Figure 1d ). These results indicate that the expression of t-PA, u-PA and metalloproteases is independently regulated in pancreatic cells and that, among them, only t-PA is strongly associated with the neoplastic phenotype.
Expression and membrane localization of annexin II and u-PAR in pancreatic epithelial cells
Because PA receptors may focus proteolytic activity at the cell membrane, thus increasing cell invasiveness, we examined PA receptor expression in cultured pancreatic cells. The expression of annexin II and u-PAR in lysates from pancreas cancer cells and NPC was determined by Western blotting. Annexin II is detected both in NPC and in cancer cells, with higher levels in SK-PC-1 and AsPC-1 cells ( Figure 2a ). u-PAR is also detected in NPC, but levels are higher in IMIM-PC-2, IMIM-PC-1, and AsPC-1 cancer cells ( Figure  2b ): two major components are present with a relative mobility of 45 ± 65 kDa, likely identifying dierent glycosylated forms (Behrendt et al., 1990; Ploug et al., 1991) . The membrane localization of u-PAR is a controversial issue (Bohuslav et al., 1995; Limongi et al., 1995; Stahl and Mueller, 1995; Stefansson and Lawrence, 1996) . To determine the localization of u-PAR and annexin II, we used SK-PC-1 cells labeled apically or basolaterally by domain selective membrane biotinylation. Cells were lysed and biotinylated surface proteins, captured with streptavidin-agarose, were identi®ed by Western blotting (Figure 2c ). Both PA receptors are exclusively detected in the basolateral membrane compartment. MUC1 and epidermal growth factor receptor (EGFr), used as controls for apical (Carrato et al., 1994) and basolateral proteins, respectively, showed the expected membrane distribution.
Therefore, PA receptors are expressed at higher levels in tumor pancreas cells, and are speci®cally localized at the basolateral membrane.
SK-PC-1 cell invasiveness in vitro depends on both t-PA and u-PA activity
We determined the invasive potential of SK-PC-1 cells expressing high levels of t-PA and u-PA using Matrigel-coated Transwell ®lters. The blockade of the proteolytic activity of each of these proteases by using speci®c inhibitors allowed us to determine their individual contribution to the process of cell invasion. Figure 3 shows that, in the presence of neutralizing antibodies to t-PA, cell invasiveness is reduced to 55.2+21% (P=0.018); this eect is not observed upon incubation with control antibodies (95.3+13.4%, P=0.83). Pefabloc/t-PA (15 mM), a synthetic derivative of benzamidine that selectively inhibits t-PA activity (StuÈ rzebecher and Markwardt, 1988) reduces invasion to 54.3+14.5% (P=0.05). The simultaneous addition of anti-t-PA antibody and Pefabloc/t-PA further decreases cell invasiveness to 32+21% of control (P=0.05). In the presence of amiloride (0.2 mM), a selective inhibitor of u-PA activity (Vassalli and Belin, 1987) , invasiveness is reduced to 40.2+19.9% of control (P=0.006). EACA decreases cell invasion to 75.2+35% (P=0.07), suggesting that plasminogen binding to membrane lysine residues is also necessary for this process. The combination of amiloride (0.02 mM) and Pefabloc/t-PA (15 mM) induced a signi®cantly more potent inhibition of cell invasiveness than either of the two agents alone (P50.05); at the doses tested, an additive eect was demonstrated (data not shown). Thus, both t-PA and u-PA proteolytic activities contribute to the invasive capacity of SK-PC-1 cells in vitro. In normal pancreas tissue, all epithelial cells in the exocrine and endocrine components are unreactive with anti-t-PA antibodies (Figure 4 ). In these assays, a strong reaction with vascular endothelial cells is observed, as previously reported (De Vries et al., 1994) . In contrast, immunoreactive t-PA is detected in 16/17 ductal-type adenocarcinomas and expression is localized both in the cytoplasm and in the lumen of tumor glands (Figure 4b ). In normal tissue, annexin II is weakly detected in connective tissue ®broblasts surrounding normal ducts but not in epithelial cells (Figure 4c ). However, in tumors (Figure 4d ), annexin II is detected in neoplastic cells in 5/13 cases (Table  1) .
Anti u-PA antibodies are unreactive with all cell types in the normal exocrine and endocrine pancreas ( Figure 5a ) and are weakly reactive with 3/14 ductal adenocarcinomas (Figure 5b ). By contrast, u-PAR is weakly detected in normal acinar and ductal cells (Figure 5d ) but it is overexpressed in the majority of tumors examined (14/15) (Figure 5e ). Because most samples examined corresponded to primary tumors and were moderately dierentiated, it was not possible to determine an association of the expression of PAs and their receptors with tumor progression or dierentiation degree (data not shown).
To determine if the overexpression of t-PA and u-PAR is restricted to tumor cells, areas of chronic obstructive pancreatitis adjacent to pancreatic cancers were also examined. As shown in Table 1 , t-PA and annexin II are generally undetectable in pancreatitis, whereas u-PA and its receptor are strongly expressed in these areas (Figure 5c and f) . These results indicate that pancreatic tumors have increased expression of t-PA and u-PAR; however, while the former is restricted to pancreas cancer cells, the latter is not.
Association of t-PA expression and genetic alterations in pancreas cancer
Because there is indirect evidence indicating that PA promoters can be regulated by signal transduction pathways involving ras and p53 (Axelrod et al., 1989; Jankun et al., 1991; Lengyel et al., 1995) , we investigated the association of t-PA expression and K-ras or p53 mutations. K-ras and p53 mutations in pancreatic tumors and cell lines were previously determined (Kaltho et al., 1993; Berrozpe et al., 1994, and unpublished results) . Table 2 shows that 6/8 cell lines secreting high levels of t-PA contain K-ras codon 12 mutations while the latter are present only in 1/4 lines that lack t-PA secretion. In addition, 9/12 tumors expressing t-PA contain K-ras codon 12 mutations. A combined analysis of the association between t-PA production and K-ras mutations in cell lines and tumors showed a signi®cant association (P=0.04). Regarding p53 mutations, no association with t-PA production was observed (P=0.586). These ®ndings suggest that K-ras gene mutations may contribute to the activation of t-PA expression in exocrine pancreatic cancer.
Discussion
The major novel ®ndings described in this paper can be summarized as follows: ®rst, t-PA is commonly expressed in pancreas cancer tissues and cell lines and appears to be selectively associated with the neoplastic phenotype; second, in vitro, both t-PA and u-PA contribute to the invasive behavior of pancreas cancer cells; third, in the neoplastic pancreas, concomitant expression of u-PA and its receptor are mainly associated with areas of pancreatitis; fourth, K-ras There is little information regarding the expression of the plasmin proteolytic system components in exocrine pancreatic cancer. The results from our studies indicate that expression of PAs in these tumors diers considerably from the ®ndings reported in other tumor types. Thus, t-PA but not u-PA is the most commonly expressed PA in pancreas tumors and it is detected in tumor cells rather than in the stroma. In contrast, in breast and colon cancer, for example, u-PA is mainly produced by stromal cells whereas u-PAR is mostly produced by cancer cells and macrophages (Nielsen et al., 1996; Pyke et al., 1991) . Although in vitro both proteases contribute to cellular invasion, our ®ndings suggest that t-PA is the main PA associated with the neoplastic process while u-PA/u-PAR, which are detected in tumor as well as in non-neoplastic epithelial cells, would be more likely involucrated in tissue remodeling.
Regarding its mechanism of action, t-PA has been mainly implicated in ®brinolysis because it is dependent on ®brin binding for its action (Carmeliet et al., 1994) . Nevertheless, deposition of ®brin in tumors is a common event (Dvorak, 1986) and, given the important desmoplastic reaction characteristic of pancreas cancer, overexpression of t-PA might be an eective proteolytic pathway of tumor invasion in this organ. t-PA can also act through cell surface receptors: annexin II in endothelial cells and amphoterin, a member of the high mobility group 1 proteins, in neuroectodermal cells (Parkkinen and Rauvala, 1991) . Annexin II is a peripheral membrane protein bound to phospholipids through calcium dependent interactions and it functions as a receptor for both t-PA and plasminogen, thus focalizing and amplifying the activity of this protease on the surface of endothelial cells (Cesarman et al., 1994; Hajjar et al., 1994 Hajjar et al., , 1996 . Increased expression of annexin II has been reported in several tumor types, including pancreas tumor cell lines (Vishwanatha et al., 1993; Davis and Vishwanatha, 1995) . It is not clear where annexin II is exactly located in the cell (reviewed in Moss, 1997) . The demonstration that t-PA is implicated in in vitro matrix invasion of pancreas cancer cells and that invasive cells express high levels of annexin II localized at the basolateral membrane, favour a yet undescribed mechanism of tumor invasion mediated by t-PA bound to its surface receptor. The co-expression of t-PA and amphoterin at the leading edge of growing neurites (Parkkinen and Rauvala, 1991; Parkkinen et al., 1993) and the t-PAstimulated migration of PC12 cells (Pittman and Di Benedetto, 1995) suggest a similar mechanism for extracellular matrix invasion.
In agreement with previous reports describing u-PAR and u-PA at focal contact points (Pollanen et al., 1987 (Pollanen et al., , 1988 or u-PAR association with b1 and b2 integrins (Bohuslav et al., 1995; Stefansson and Lawrence, 1996; Wei et al., 1996) we found u-PAR to be localized in the basolateral membrane in SK-PC-1 cells. This ®nding does not exclude the presence of the receptor in other membrane compartments, such as caveolae (Stahl and Mueller, 1995; Limongi et al., 1995; Paciucci et al., submitted) , where, possibly, protein availability for surface biotinylation reactions is decreased. In this respect, we have shown that in IMIM-PC-2 cells the proteolytically activated u-PAR (Resnati et al., 1996) is not localized in caveolae and corresponds to the form associated with the motile phenotype (Paciucci et al., submitted) . Thus, we suggest that u-PAR localized in the basolateral membrane is the form involved in in vitro invasion of pancreas tumor cells.
With respect to the mechanisms responsible for u-PA and u-PAR overexpression in peritumoral pancreatitis, it is possible that the in¯ammatory cells present in this lesion contribute to their activation. The u-PA and u-PAR promoters can in fact be activated by phorbol esters, cytokines, such as TNFa (reviewed by Medcalf et al., 1990; Kwaan, 1992; Wang et al., 1994) , TGF b1, EGF (Lund et al., 1991; Medcalf et al., 1991) and HGF (Pepper et al., 1992; Jeers et al., 1996) . Further studies are needed to establish whether u-PA/ u-PAR overexpression in pre-neoplastic pancreatic lesions play a role in early stages of tumor progression.
One question raised by our study is the molecular basis of t-PA activation of expression in pancreas cancers. Cells transformed by activated ras proteins overexpress u-PA and t-PA and show enhanced invasion and metastatic abilities, while cells containing mutated p53 proteins lose the ability to repress the expression of both t-PA and u-PA, suggesting that the genetic alterations present in tumors may participate in activating PA expression (Axelrod et al., 1989; Jankun et al., 1991; Kunz et al., 1995; Lengyel et al., 1995) . These evidences, together with the association between codon 12 K-ras mutations and t-PA expression Kaltho et al. (1993) , and unpublished results.
b Expression in pancreatic cancer cell lines and tumors determined by ELISA (nanograms of secreted t-PA/24h/micrograms of total cellular protein) and immunohistochemistry respectively. b.d. Below detectable levels. n.d. Not done t-PA in pancreas cancer R Paciucci et al described here, suggest that K-ras activation is one of the mechanisms contributing to t-PA induction in pancreatic cancer. The role t-PA in tumor cell invasion needs to be explored in vivo. Our ®ndings suggest that the contribution of t-PA overexpression to the aggressive behavior of pancreatic tumors may be severalfolds: (i) through direct activation of growth factors; (ii) through activation of plasmin, which, in turn, activates growth factors and latent metalloproteases shown to be produced in these tumors (this work and Gress et al., 1995) ; (iii) through activation of plasmin which directly degrades extracellular matrix proteins and allows tumor cell invasion. Considering its anatomical characteristics, these mechanisms may be sucient to allow invasion in the pancreas while additional ones might be necessary for invasion in other tissues, such as colon, where the tumor has to invade a thick muscle layer. The results reported here emphasize the need to examine the role of t-PA in pancreas cancer progression in greater depth.
Materials and methods
Cell culture and reagents
IMIM-PC-1 and IMIM-PC-2 cell lines were established at the Institut Municipal d'InvestigacioÂ MeÁ dica (Barcelona, Spain) and SK-PC-1 and SK-PC-3 were established at the Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center (New York, USA) (VilaÂ et al., 1995a). SW850, SW979 and QGP-1 cells were obtained from Dr H Kaltho (Christian-AlbrechtsUniversity, Kiel, Germany). Other cell lines were obtained from the American Type Culture Collection (Rockville, MD). All cell lines are derived from ductal adenocarcinomas, except for QGP-1 which is from endocrine origin. Pancreas cancer cells were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) (GIBCO-BRL, Gaithersburg, MA) supplemented with 10% of heatinactivated fetal bovine serum (FBS) (GIBCO-BRL) at 378C in 5% CO 2 atmosphere. Fresh normal pancreas tissue was obtained from organ donors and processed as described in order to isolate the exocrine component, and the characteristics of normal exocrine pancreas cultures (NPC) have been described (VilaÂ et al., 1994b) . Matrigel was purchased from Becton Dickinson (Bedford, MA), amiloride was from Sigma (St Louis, MO), and Pefabloc/ t-PA was purchased from Pentapharm (Basel, Switzerland).
Antibodies
Neutralizing goat antibodies recognizing u-PA (ref. 398) or t-PA (ref. 387) were purchased from American Diagnostica (Greenwich, CT). Rabbit anti-u-PAR antibody was a kind gift of Dr D Talarico (Ospedale San Raaele, Milano, Italy). Mouse monoclonal anti-annexin II antibody was from Transduction Laboratories (Lexington, KY). Rabbit polyclonal serum detecting EGFr (4/17) was obtained from Dr S Decker (Rockefeller University, NY), and mouse anti-MUC1 monoclonal antibody BC3 was provided by Dr IFC McKenzie (Austin Research Institute, Heidelberg, Australia). Peroxidase-coupled goat antibodies detecting mouse Ig or rabbit Ig were purchased from Dakopatts (Glostrup, Denmark). Biotin-labeled mouse anti-goat Ig was from Pierce (Rockford, IL) and peroxidase-coupled streptavidin was from Zymed (San Francisco, CA). Control normal goat serum was from Sigma.
Northern blot analysis
Total cellular RNA was isolated by acid guanidinium thiocyanate-phenol-chloroform extraction procedure (Sacci and Chomczynski, 1987) . Total RNA (10 mg) from cultured cells or tissue was fractionated in 1% agarose-formaldehyde gels, transferred to nylon ®lters, and hybridized to probes labeled with a 32 PdCTP by random priming (Feinburg and Volgelstein, 1983) . Hybridizations were carried out overnight at 428C, followed by washing with 0.26SSC and 1% SDS at 608C followed by autoradiography. The quality and quantity of the transferred RNA were assessed by ethidium bromide staining of ribosomal RNAs.
Enzyme-linked immunosorbent assay (ELISA)
Maxisorb plates (Nunc, Naperville, IL) were coated with conditioned serum-free medium, washed with PBS, and incubated with gelatin (1% in PBS). Anti-t-PA antibodies (2 mg/ml in 0.1% Tween 20 in PBS) were added for 1 h at 378C and plates were washed with PBS/Tween. Biotinlabeled mouse anti-goat IgG (diluted 1/50 000 in PBS/ Tween) was added for 1 h at 378C and, after washing, alkaline phosphatase-coupled streptavidin (Zymed) was added for an additional 1 h at 378C (1/4000 dilution in PBS/Tween). After washing, reactions were developed using 4-methylumbelliferyl phosphate (Boehringer Mannheim, Barcelona, Spain) (1 mg/ml in triethanolamine buer pH 9.5). Puri®ed t-PA (Actilyse, Boehringer Mannheim) was used as a standard. A Cyto¯uor 2300 system (Millipore, Bedford, MA) was used to measure the reaction products.
Western blotting
Cells from precon¯uent cultures were lysed at 48C in 20 mM Tris pH 6.8, 1% Triton X-100, 3 mM MgCl 2 , 50 mM NaCl and 300 mM sucrose. After centrifugation for 10 min at 13 000 g, proteins from the soluble fraction (50 mg) were fractionated by SDS ± PAGE and transferred to nitrocellulose ®lters. To enrich for glycosylated proteins, cell lysates (200 mg of protein) were fractionated by anity chromatography on Concanavalin A-Sepharose equilibrated in buer A (10 mM Tris pH 7.4, 150 mM NaCl, 0.1% NP40). Glycoproteins were eluted with buer A supplemented with 1 M a-methyl-mannoside. The rest of the procedure was carried out as previously described using a peroxidase-labeled secondary antibody (VilaÂ et al., 1995b) .
Domain-selective biotinylation assays
Selective biotinylation of SK-PC-1 cells was performed as described (Lisanti et al., 1990) . Brie¯y, cells were seeded in 0.4 mm pore Transwells (Costar) until con¯uence. When the monolayer was impermeable, cells were washed with cold Dulbecco's PBS (D-PBS), and sulfo-NHS-biotin (Pierce) (0.5 mg/ml) was added to the apical or basolateral compartment for 20 min at 48C. After washing with cold D-PBS, cells were incubated with DMEM without FBS for 15 min at 48C, washed with cold D-PBS, lysed in 1% Triton X-100, 50 mM Tris-HCl pH 8, 62.5 mM EDTA supplemented with protease inhibitors, and fractionated with streptavidin-agarose. Biotinylated proteins were resolved by 9% SDS ± PAGE and identi®ed by Western blotting using speci®c antibodies. Antibodies recognizing MUC1 and EGFr were used as controls of the apical and basolateral selective biotinylation reactions.
Zymography
Twenty-four hours conditoned medium from cells cultured in DMEM without FBS was centrifuged at 13 000 g for t-PA in pancreas cancer R Paciucci et al 15 min at 48C. Sample volumes to be used in the zymography assay were determined on the basis of protein concentration in the soluble fraction of the cell lysates and proteins were separated by 10% SDS ± PAGE in plasminogen-and/or gelatin-containing gels, as described elsewhere (Heussen and Dowdle, 1980) . The protease activity was revealed by incubating the gels in 2.5% Triton X-100 for 1 h followed by incubation in 0.1 M glycine pH 8.3 overnight at 378C. After ®xing proteins with methanol/ acetic acid/water (30 : 10 : 60), gels were stained with 0.1% amido black and destained.
Immunohistochemical methods
Normal pancreas tissue was obtained from organ donors and tumor samples were obtained from surgical specimens. Tissues were snap frozen in liquid nitrogen or in isopenthane cooled at 7808C and stored at 7808C until used. Five micron sections of frozen tissues were ®xed in cold acetone for 10 min and used in immunohistochemical assays. The indirect immunoperoxidase method was used, as described elsewhere (Carrato et al., 1994) . Reactions were scored as (+++) when staining was clearly seen at the 6100 magni®cation, (++) when it was clearly seen 6200 magni®cation, and (+) when de®nite staining could only be seen at the 6400 magni®cation. In all assays, control normal goat serum or an irrelevant mouse mAb were used and found to be unreactive. The concentration of antibodies used in these assays were: anti-t-PA, 10 mg/ ml; anti-u-PA, 5 mg/ml; anti-annexin II, 15 mg/ml; anti-u-PAR, 1 : 500 dilution.
In vitro invasion assays
The invasive potential of cultured tumor cells was tested using Matrigel-coated Transwell ®lters (Costar, Cambridge, MA). Matrigel diluted 1 : 20 in PBS, was used to coat ®lters (50 ml) and allowed to dry overnight under u.v. light. Cells (4610 4 ) were plated on top of Matrigel in DMEM witout FBS supplemented with 1% BSA. DMEM containing 10% FBS was placed on the bottom wells. Speci®c protease inhibitors were added to both top and bottom wells. To inhibit t-PA proteolytic activity neutralizing anti-t-PA antibody (150 mg/ml) or Pefabloc/t-PA (15 mM) were added; u-PA proteolytic activity was inhibited by adding 0.2 mM amiloride, and plasminogen binding to cell membranes was competed by addition of EACA (50 mM). Anti t-PA antibody was tested at 100 and 150 mg/ml and no toxicity on cells was detected at these concentrations. Amiloride at the concentration of 0.02, 0.2, and 2 mM, EACA at 10, 50 and 150 mM and Pefabloc at 15, 50 and 100 mM were determined not to be toxic for the cells. Plates were incubated at 378C for 72 h and cells that invaded Matrigel and passed to the lower compartment of the ®lters were visualized by ®xation with 1% glutaraldehyde and staining with 0.2% crystal violet. Quantitative determinations were obtained using overnight 3 H-thymidine-labeled cells (2 mCi/10 5 cells/ml) plated on top of Matrigel. After carefully removing the Matrigel and the cells present on the top part of the ®lters, these were cut and radioactivity was quantitated in a beta scintillation counter. All assays were carried out in triplicate and at least two independent experiments were performed.
K-ras and p53 mutation detection
The association between t-PA expression and K-ras mutations was established using data from prior studies (Kaltho et al., 1993; Berrozpe et al., 1994) and our own unpublished data using PCR ampli®cation and the arti®cial restriction fragment length polymorphism strategy (Malats et al., 1997) . p53 mutation data, pooled from prior studies, were obtained using direct sequencing of PCR amplification products (Kaltho et al., 1993; Berrozpe et al., 1994) .
Statistical analysis
The eect of various agents on cell invasiveness, as a continuous variable, was compared with the control experimental conditions using the Mann ± Whitney test. The association of t-PA expression (+or7) and K-ras or p53 mutations (dichotomous variables) was assessed by Fisher's exact test.
Abbreviations EACA, epsilon aminocaproic acid; EGF, epidermal growth factor; FBS, fetal bovine serum; HGF, hepatocyte growth factor; NPC, normal exocrine pancreatic cultures; TGF, transforming growth factor; TNF, tumor necrosis factor; t-PA, tissue-plasminogen activator; u-PA, urokinase-type plasminogen activator; u-PAR, urokinase-type plasminogen activator receptor.
